Get the Stockscreener App
1.97
1.03%
0.02
After Hours:
1.96
-0.01
-0.51%
Iovance Biotherapeutics Inc stock is traded at $1.97, with a volume of 10.84M.
It is up +1.03% in the last 24 hours and down -9.22% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$1.95
Open:
$1.97
24h Volume:
10.84M
Relative Volume:
0.89
Market Cap:
$712.85M
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-1.6016
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
-12.44%
1M Performance:
-9.22%
6M Performance:
-45.13%
1Y Performance:
-81.13%
1-Day Range:
$1.94
$2.00
1-Week Range:
$1.93
$2.35
52-Week Range:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.97 | 705.62M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Is Iovance Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 News Drivers & AI Powered Market Entry Ideas - newser.com
Can Iovance Biotherapeutics Inc. stock deliver strong Q4 earningsMarket Movement Recap & Fast Entry Momentum Alerts - newser.com
What Wall Street predicts for Iovance Biotherapeutics Inc. stock price2025 Valuation Update & Stepwise Entry and Exit Trade Signals - newser.com
Is Iovance Biotherapeutics Inc. stock poised for growth2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
Iovance Biotherapeutics (IOVA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Why Iovance Biotherapeutics Inc. stock appeals to analystsTrade Volume Report & High Return Stock Watch Alerts - newser.com
Using RSI to spot recovery in Iovance Biotherapeutics Inc.Earnings Trend Report & Growth Focused Stock Reports - newser.com
Why Iovance Biotherapeutics Inc. stock is favored by top institutionsPortfolio Return Report & Consistent Income Trade Ideas - newser.com
Will Iovance Biotherapeutics Inc. stock see PE expansionJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
How big funds are accumulating Iovance Biotherapeutics Inc. (2LB) stock2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - newser.com
Published on: 2025-10-31 02:59:28 - newser.com
How Iovance Biotherapeutics Inc. stock trades during market volatility2025 Trading Recap & Daily Entry Point Trade Alerts - newser.com
How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stockTrend Reversal & Verified Technical Signals - newser.com
Will Iovance Biotherapeutics Inc. stock gain from lower inflationJuly 2025 Highlights & Fast Moving Market Watchlists - newser.com
Automated trading signals detected on Iovance Biotherapeutics Inc.Market Movement Recap & Daily Chart Pattern Signal Reports - newser.com
Why analysts upgrade Iovance Biotherapeutics Inc. stock2025 Trade Ideas & Stepwise Trade Signal Implementation - newser.com
What MACD trends signal for Iovance Biotherapeutics Inc. (2LB) stockTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 6.2% After Analyst Downgrade - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $9.00 Price Target at HC Wainwright - MarketBeat
Is it time to cut losses on Iovance Biotherapeutics Inc.July 2025 Trends & Weekly Setup with ROI Potential - newser.com
Will Iovance Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Decliners & High Conviction Buy Zone Picks - newser.com
Iovance Biotherapeutics, Inc. Securities Lawsuit Investigation - Claim Depot
Using portfolio simulators with Iovance Biotherapeutics Inc. includedTreasury Yields & Weekly Chart Analysis and Trade Guides - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock fits value portfoliosDay Trade & Smart Allocation Stock Reports - newser.com
Can trapped investors hope for a rebound in Iovance Biotherapeutics Inc.July 2025 Review & Capital Efficiency Focused Strategies - newser.com
Published on: 2025-10-30 00:18:19 - newser.com
What insider trading reveals about Iovance Biotherapeutics Inc. stockFed Meeting & High Accuracy Swing Entry Alerts - newser.com
IOVA: Analyst Lowers Price Target to $9.00 While Maintaining 'Bu - GuruFocus
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Valuation Update: Can Iovance Biotherapeutics Inc. stock deliver consistent earnings growthJuly 2025 Gainers & Long Hold Capital Preservation Plans - Fundação Cultural do Pará
Can Iovance Biotherapeutics Inc. stock outperform in 2025 bull market2025 Market WrapUp & Community Consensus Picks - Fundação Cultural do Pará
Can Iovance Biotherapeutics Inc. stock surprise with earnings upsideJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - Fundação Cultural do Pará
Can Iovance Biotherapeutics Inc. stock deliver consistent earnings growth2025 Volume Leaders & AI Powered Market Trend Analysis - Fundação Cultural do Pará
Can Iovance Biotherapeutics Inc. stock beat market expectations this quarterEarnings Risk Summary & Real-Time Volume Triggers - Fundação Cultural do Pará
Regression analysis insights on Iovance Biotherapeutics Inc. performanceBull Run & Safe Entry Trade Signal Reports - newser.com
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersTrade Risk Report & Daily Price Action Insights - newser.com
Published on: 2025-10-28 00:32:54 - newser.com
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Jun 05 '25 |
Buy |
1.84 |
30,000 |
55,200 |
30,000 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):